Proof of concept of randomized controlled study of Curcumin C3 Complex® as adjunct treatment in Schizophrenia: effects on negative and depressive symptoms

Cultivating Natural Bioactives: International Conference July 9 to 11, 2012.

 

For the first time the study demonstrates the efficacy of Curcumin C3 Complex®, when combined with BioPerine® as a metabolic enhancer in schizophrenia and also highlights the significance of targeting epigenetics signal pathway in schizophrenia.

 

Study Design:

Authors designed a parallel group randomized trial (15 subjects) of schizophrenia with persisted negative symptoms.

 

Results and Discussion:

It was observed that both 1 g and 4 g Curcumin groups improved in their negative symptoms over 12 weeks. On the neurocognitive domain, the C-3 treated groups demonstrated positive change in overall neurocognitive index. Curcumin was highly tolerated with no serious adverse events.

 

Conclusion:

Curcumin C3 Complex® is safe and active in improving the negative and depressive symptoms in schizophrenia.

About Sabinsa

Sabinsa Corporation is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

HeadQuarters

Sabinsa Corporation

20 Lake Drive 

East Windsor,

NJ 08520, USA

Tel: +1 732 777 1111

Fax: +1 732 777 1443

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Contact Presence